RS is a feasible alternative to SCC for ECT, with acceptable recovery and fewer side effects without affecting the seizure duration. However, larger high-quality randomized controlled trials are necessary to statistically substantiate these findings and assess the long-term outcomes.
Anand et al. (Thu,) studied this question.